51 results
Page 2 of 3
S-3ASR
9z1 oeq6211e1a7
23 Sep 22
Automatic shelf registration
4:08pm
8-K
EX-99.1
lsl tny7fnl8gg
9 Aug 22
Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
6:45am
424B5
s0oe75hrnb9dudmm
21 Jul 22
Prospectus supplement for primary offering
4:43pm
424B5
bpta6
20 Jul 22
Prospectus supplement for primary offering
4:22pm
8-K
mczwq5t
12 Jul 22
Other Events
7:00am
S-3
wq77sfdxsm h082h1i
1 Jul 22
Shelf registration
4:36pm
8-K
EX-99.1
p2f6e4
10 May 22
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023
6:48am
DEF 14A
gj1clhg
29 Apr 22
Definitive proxy
7:01am
10-K
69vbw v6vydovi4j3f
14 Mar 22
Annual report
7:04am
8-K
EX-99.1
lnleus2bc0nrqeidj
14 Mar 22
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
6:49am
8-K
EX-99.1
3v7cglg7emiszeyg
10 Nov 21
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results
6:56am
10-Q
rr0c67giayza hiw6w2
12 Aug 21
Quarterly report
8:53am
8-K
EX-99.1
sa4kae u59alx1otpha
12 Aug 21
Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
8:20am
424B4
r0mh2t9p0
17 Jun 21
Prospectus supplement with pricing info
4:50pm
S-1/A
ol2z1pvfngohfatl
14 Jun 21
IPO registration (amended)
6:15am